Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?

Hatem S Shehata, Mohamed S El-Tamawy, Nevin M Shalaby, Gihan Ramzy, Hatem S Shehata, Mohamed S El-Tamawy, Nevin M Shalaby, Gihan Ramzy

Abstract

Background: Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, mostly by acting on neurogenic inflammatory mediators and controlling the neurotransmitter release of sensory and autonomic nerve terminals that are involved in many chronic painful conditions as chronic intractable trigeminal neuralgia (TN).The aim of our work was evaluating the efficacy, safety, and tolerability of BTX-A for the treatment of intractable idiopathic TN.

Methods: This was a randomized, single-blinded, placebo-control study carried out on 20 Egyptian patients with intractable TN. Patients received a one-time subcutaneous administration of BTX-A using "follow the pain" method. The primary efficacy measure was reduction in pain severity on the 10-cm VAS score as well as in paroxysms frequency from the baseline to week 12 (endpoint last observation carried forward [LOCF]). Secondary efficacy measures included QoL assessment and number of acute medications received from baseline to the endpoint.

Results: Pain reduction at the 12-week endpoint was significant in BTX-A group (p<0.0001); VAS scores at endpoint LOCF relative to baseline for BTX-A group showed a decrease of 6.5 compared with a decrease of 0.3 for placebo, also there was a significant decrease in the number of acute medications and an increase in QoL functioning scale.

Conclusion: These results indicate that BTX-A has a direct analgesic effect in patients with TN and can represent a therapeutic option for intractable cases.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Mean scores of VAS during follow up visits.

References

    1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia. 2004;24(Suppl 1):9–160.
    1. Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract. 2006;6:153–160. doi: 10.1111/j.1533-2500.2006.00079.x.
    1. Taylor JC, Brauer S, Espir MLE. Long term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J. 1981;57:16–18. doi: 10.1136/pgmj.57.663.16.
    1. Dalessio DJ. Trigeminal neuralgia. A practical approach to treatment. Drugs. 1982;24(3):248–255. doi: 10.2165/00003495-198224030-00005.
    1. Cruccu G, Truini A. Refractory trigeminal neuralgia. Non-surgical treatment options. CNS Drugs. 2013;27(2):91–96. doi: 10.1007/s40263-012-0023-0.
    1. Taha JM, Tew JM Jr. Treatment of trigeminal neuralgia by percutaneous radiofrequency rhizotomy. Neurosurg Clin N Am. 1997;8(1):31–39.
    1. Tatli M, Satici O, Kanpolat Y, Sindou M. Various surgical modalities for trigeminal neuralgia: literature study of respective long-term outcomes. Acta Neurochir (Wien) 2008;150(3):243–255. doi: 10.1007/s00701-007-1488-3.
    1. Allam N, Brasil-Neto JP, Brown G, Tomaz C. Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain. 2005;21(2):182–184. doi: 10.1097/00002508-200503000-00010.
    1. Türk U, Ilhan S, Alp R, Sur H. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol. 2005;28(4):161–162. doi: 10.1097/01.wnf.0000172497.24770.b0.
    1. Woo Seog S. Application of Botulinum toxin in pain management. Korean J Pain. 2011;24(1):1–6. doi: 10.3344/kjp.2011.24.1.1.
    1. Zakrzewska JM. Botulinum toxin for trigeminal neuralgia–do we have the evidence? Caphalalgia. 2012;32(15):1154–1155. doi: 10.1177/0333102412459577.
    1. American chronic pain association. 2003. .
    1. Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F, Moharamnejad N. Use of botulinum toxin a for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:47–50. doi: 10.1016/j.tripleo.2010.04.043.
    1. Zuniga C, Diaz S, Piedimonte F, Micheli F. Beneficial effects of botulinum toxin type a in trigeminal neuralgia. Arq Neuropsiquiatr. 2008;66:500–503. doi: 10.1590/S0004-282X2008000400012.
    1. Ngeow WC, Nair R. Injection of botulinum toxin type A (botox) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:e47–50.
    1. Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013;4(2):10. doi: 10.1177/2042533312472115.
    1. Chen WT, Yuan RY, Chiang SC, Sheu JJ, Yu JM, Tseng IJ, Yang SK, Chang HH, Hu CJ. Onabotulinumtoxin A improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain. 2013;29(4):305–310. doi: 10.1097/AJP.0b013e318255c132.
    1. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–133. doi: 10.1016/j.pain.2003.10.008.
    1. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97:1108–1116.
    1. Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35–43. doi: 10.1111/j.1526-4610.2004.04007.x.
    1. Meng J, Wang J, Lawrence G, Dolly O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120:2864–2874. doi: 10.1242/jcs.012211.
    1. Meng J, Ovsepian SV, Wang J, Pickering M, Saase A, Aoki KR, Lawrence GW, Dolly JO. Activation of TRPV 1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29:4981–4992. doi: 10.1523/JNEUROSCI.5490-08.2009.
    1. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785–793. doi: 10.1016/j.neuro.2005.01.017.
    1. Matak I, Bach-Rojecky L, Filipović B, Lacković Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;86:201–207.
    1. Filipović B, Matak I, Bach-Rojecky L, Lacković Z. Central action of peripherally applied Botulinum toxin type a on pain and dural protein extravasation in Rat model of trigeminal neuropathy. PLoS One. 2012;7(1):e29803. doi: 10.1371/journal.pone.0029803. doi: 10.1371/journal.pone.0029803.
    1. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18(suppl):S125–132.
    1. Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. Botulinum toxin successfully treats trigeminal neuralgia. Neurology. 2005;20:24.
    1. Hu Y, Guan X, Fan L, Li M, Liao Y, Nie Z, Jin L. Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain. 2013;14:72. doi: 10.1186/1129-2377-14-72.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren